Changing strategies for target therapy in gastric cancer
- Authors
- Lee, Suk-young; Oh, Sang Cheul
- Issue Date
- 21-1월-2016
- Publisher
- BAISHIDENG PUBLISHING GROUP INC
- Keywords
- Advanced gastric cancer; Target therapy; Chemotherapy; Strategy; Signal pathway
- Citation
- WORLD JOURNAL OF GASTROENTEROLOGY, v.22, no.3, pp.1179 - 1189
- Indexed
- SCIE
SCOPUS
- Journal Title
- WORLD JOURNAL OF GASTROENTEROLOGY
- Volume
- 22
- Number
- 3
- Start Page
- 1179
- End Page
- 1189
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/89773
- DOI
- 10.3748/wjg.v22.i3.1179
- ISSN
- 1007-9327
- Abstract
- In spite of a worldwide decrease in the incidence of gastric cancer, this malignancy still remains one of the leading causes of cancer mortality. Great efforts have been made to improve treatment outcomes in patients with metastatic gastric cancer, and the introduction of trastuzumab has greatly improved the overall survival. The trastuzumab treatment took its first step in opening the era of molecular targeted therapy, however several issues still need to be resolved to increase the efficacy of targeted therapy. Firstly, many patients with metastatic gastric cancer who receive trastuzumab in combination with chemotherapeutic agents develop resistance to the targeted therapy. Secondly, many clinical trials testing novel molecular targeted agents with demonstrated efficacy in other malignancies have failed to show benefit in patients with metastatic gastric cancer, suggesting the importance of the selection of appropriate indications according to molecular characteristics in application of targeted agents. Herein, we review the molecular targeted agents currently approved and in use, and clinical trials in patients with metastatic gastric cancer, and demonstrate the limitations and future direction in treatment of advanced gastric cancer.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Graduate School > Department of Biomedical Sciences > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.